Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Nishinomiya, Hyogo, Japan Clinical Trials

A listing of Nishinomiya, Hyogo, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (28) clinical trials

FASENRA SCEI for Long-term Use

The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe. Detection of unexpected Adverse Drug Reactions To grasp development of Adverse Drug Reactions To grasp contributing factors possibly having an impact on the safety and efficacy Development ...

Phase N/A

9.55 miles

Learn More »

Development of Visual Function Evaluation Method (2)

The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient.

Phase N/A

9.55 miles

Learn More »

IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy

To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in patients with locally advanced unresectable non-small cell lung cancer who are treated with the product as maintenance therapy ...

Phase N/A

9.55 miles

Learn More »

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

This is a post-marketing long-term specified drug use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients ...

Phase N/A

9.55 miles

Learn More »

Brilinta Clinical Experience Investigation

To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on ...

Phase N/A

9.55 miles

Learn More »

A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

This is a post-marketing use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients (including withdrawals and ...

Phase N/A

9.55 miles

Learn More »

Lynparza Breast Cancer Clinical Experience Investigation

To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.

Phase N/A

9.55 miles

Learn More »

Dominantly Inherited Alzheimer Network (DIAN)

Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and is an important model for study because the responsible mutations have known biochemical consequences that are believed to underlie the pathological basis of the disorder. Three major hypotheses will be tested: First, that there is ...

Phase N/A

9.61 miles

Learn More »

Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)

Clinical studies for fomepizole intravenous infusion have not been conducted in Japan, and there are few reports of data on drug-use, including in the literature, in Japanese patients; therefore, an evaluation of the safety and efficacy of fomepizole intravenous infusion is required. This specified drug-use survey for fomepizole intravenous infusion ...

Phase N/A

9.61 miles

Learn More »

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and ...

Phase N/A

9.61 miles

Learn More »